Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Uncontrolled cancer cell replication necessitates a robust supply of deoxyribonucleoside triphosphates (dNTPs).
• Ribonucleotide reductase subunit M2 (RRM2) is a critical enzyme controlling the intracellular dNTP pool.
• Clear-cell renal cell carcinoma (ccRCC) is a significant subtype of kidney cancer.

Purpose of the Study:

• To investigate the biological and clinical significance of RRM2 in clear-cell renal cell carcinoma (ccRCC).
• To evaluate RRM2 as a potential therapeutic target in ccRCC.
• To assess the impact of RRM2 inhibition on ccRCC progression and cell viability.

Main Methods:

• Assessed RRM2 expression levels in ccRCC tissues and correlated them with disease progression and patient survival.
• Utilized small interfering RNA (siRNA) to inhibit RRM2 expression in renal cell carcinoma (RCC) cell lines.
• Administered Triapine, a specific RRM2 inhibitor, to RCC cell lines to evaluate its anti-cancer effects.
• Analyzed the effects of RRM2 inhibition on cell cycle progression and dNTP pool levels.

Main Results:

• RRM2 expression was significantly upregulated in ccRCC tissues compared to normal adjacent tissues.
• Higher RRM2 expression correlated with advanced pT stages, elevated Fuhrman grades, and reduced overall survival (OS) in ccRCC patients.
• RRM2 inhibition via siRNA or Triapine effectively suppressed RCC cell growth.
• RRM2 inhibition led to G0/G1 cell cycle arrest and dNTP pool attenuation in RCC cells.

Conclusions:

• RRM2 plays a crucial role in ccRCC pathogenesis and progression.
• RRM2 represents a promising novel therapeutic target for ccRCC treatment.
• Development of non-nucleoside, reversible small-molecule inhibitors targeting RRM2 warrants further investigation for ccRCC therapy.